Interface Dermatitis – Comprehensive Medical Guide

Overview

Interface dermatitis (also called *lichenoid dermatitis* or *interface reaction pattern*) is a group of skin conditions in which inflammatory cells attack the junction between the epidermis (the outer skin layer) and the dermis (the deeper layer). This “interface” becomes inflamed, leading to characteristic skin changes that may appear as flat, violaceous (purple‑red) patches, papules, or plaques. The pattern can be seen in several distinct diseases—including lichen planus, lupus erythematosus, and drug‑induced eruptions—so the term is descriptive rather than a single diagnosis.

Although interface dermatitis can affect people of any age, it is most common in adults aged 30–60 years. Epidemiological data are limited because the condition is usually reported as part of the underlying disease. For example, lichen planus (the classic presentation) affects roughly 0.5–1 % of the general population, and cutaneous lupus erythematosus occurs in about 5–10 % of patients with systemic lupus (1,2).

Overall, the exact prevalence of “interface dermatitis” as a histopathologic finding is unknown, but it accounts for a large proportion of skin biopsies evaluated by dermatopathologists worldwide (estimated >20 % of all skin biopsies) (3).

Symptoms

Symptoms vary according to the underlying cause, but the shared clinical features of interface dermatitis include the following:

• Violaceous or pink flat-topped papules – often intensely itchy (pruritic).
• Polygonal shape – classic “saw‑tooth” appearance in lichen planus.
• Wickham’s striae – fine white lines on the surface of papules, most visible after oil application.
• Reticular (net‑like) pattern – especially on the wrists, ankles, and trunk.
• Erythematous (red) patches – may be scaly or smooth.
• Blistering or ulceration – seen in severe drug reactions (e.g., Stevens‑Johnson syndrome) or in lupus.
• Oral lesions – white, lacy patches or painful ulcers on the buccal mucosa, tongue, or gums (common in lichen planus).
• Nail changes – ridging, thinning, or pitting of nails.
• Hair loss (alopecia) – may occur when scalp is involved.
• Systemic symptoms – fever, malaise, joint pain, or photosensitivity when the dermatitis is part of an autoimmune disease (e.g., lupus).
• Pruritus (itching) – often severe enough to disturb sleep.

Causes and Risk Factors

Interface dermatitis is a reaction pattern rather than a standalone disease. The most common etiologies include:

Autoimmune Disorders

• Lichen planus – idiopathic immune attack on basal keratinocytes.
• Cutaneous lupus erythematosus – autoantibodies target skin cells, often triggered by UV light.
• Dermatomyositis – immune‑mediated inflammation of skin and muscle.

Drug‑Induced Reactions

Medications can trigger a lichenoid drug eruption that mimics lichen planus.

• Beta‑blockers, ACE inhibitors, thiazide diuretics.
• Antimalarials (hydroxychloroquine), NSAIDs, antiretrovirals.
• Checkpoint inhibitors used in cancer therapy.

Infections

• Hepatitis C virus (strong association with lichen planus).
• Human papillomavirus (HPV) and Epstein‑Barr virus (EBV) have been implicated in some cases.

Other Triggers

• Contact allergens (nickel, fragrance, cosmetics).
• Chronic sun exposure (photosensitivity in lupus).
• Genetic predisposition – certain HLA types increase susceptibility.

Risk Factors

• Age 30‑60 years (peak incidence of lichen planus).
• Female gender – especially for lupus‑related interface dermatitis.
• Family history of autoimmune disease.
• Chronic hepatitis C infection.
• Use of implicated medications.

Diagnosis

Because interface dermatitis is a histopathologic term, diagnosis relies on a combination of clinical assessment and skin biopsy.

Clinical Evaluation

• Detailed history (onset, progression, medication list, systemic symptoms).
• Physical exam focusing on distribution, morphology, and presence of mucosal or nail lesions.

Skin Biopsy (Gold Standard)

A 4‑mm punch biopsy is taken from an active lesion and examined with hematoxylin‑eosin staining. Key microscopic features include:

• Interface vacuolar change – basal keratinocyte degeneration.
• Band-like lymphocytic infiltrate hugging the dermal‑epidermal junction.
• Colloid bodies (Civatte bodies) – apoptotic keratinocytes.
• Hypergranulosis and saw‑tooth acanthosis (especially in lichen planus).

Additional Tests (when indicated)

• Direct immunofluorescence (DIF) – to detect immunoglobulin deposits in lupus or dermatitis herpetiformis.
• Serology – ANA, anti‑dsDNA, anti‑Ro/La for lupus; Hepatitis C antibody.
• Patch testing – if contact allergy is suspected.
• Complete blood count & metabolic panel – baseline before systemic therapy.

Treatment Options

Treatment aims to control inflammation, relieve itching, and address the underlying cause.

Topical Therapies

• High‑potency corticosteroids (clobetasol 0.05 % ointment) – first‑line for limited skin disease; apply once daily for 2–4 weeks, then taper.
• Calcineurin inhibitors (tacrolimus 0.1 % ointment or pimecrolimus 1 % cream) – useful on thin skin (face, intertriginous areas) and for steroid‑sparing.
• Vitamin D analogs (calcipotriene) – adjunctive anti‑inflammatory effect.

Systemic Medications

• Oral corticosteroids (prednisone 0.5 mg/kg) – for severe or widespread disease; short courses to minimize side effects.
• Antihistamines (cetirizine, diphenhydramine) – help control pruritus.
• Acitretin (retinoid) – effective for refractory lichen planus and lupus skin lesions.
• Hydroxychloroquine – first‑line for cutaneous lupus; monitor retinal toxicity.
• Immunosuppressants (mycophenolate mofetil, methotrexate, azathioprine) – used when steroids are contraindicated or chronic control is needed.
• Biologic agents (dupilumab, secukinumab) – emerging evidence for refractory lichenoid disease.

Procedural Interventions

• Phototherapy (narrow‑band UVB or PUVA) – beneficial for extensive lichen planus; requires regular sessions.
• Laser therapy (585 nm pulsed dye laser) – can improve persistent papules or vascular lesions.
• Cryotherapy – targeted treatment of isolated lesions.

Lifestyle & Adjunct Measures

• Regular use of fragrance‑free moisturizers to restore barrier function.
• Avoidance of known triggers (specific drugs, sun exposure, irritants).
• Stress‑reduction techniques – stress can exacerbate autoimmune flares.

Living with Interface Dermatitis

Long‑term management focuses on symptom control, skin care, and monitoring for disease progression.

Skincare Routine

1. Gentle cleansing – lukewarm water and non‑soap cleansers; avoid scrubbing.
2. Moisturize within 3 minutes of bathing using a thick emollient (e.g., petrolatum, ceramide‑rich cream).
3. Sun protection – SPF 30+ broad‑spectrum sunscreen, protective clothing; especially crucial for lupus.

Itch Management

• Cool compresses or oatmeal baths.
• Topical menthol or pramoxine for short‑term relief.
• Use of nighttime antihistamines to improve sleep.

Monitoring & Follow‑up

• Schedule dermatology visits every 3–6 months, or sooner after medication changes.
• Track new lesions, mucosal involvement, or systemic symptoms in a diary.
• Annual eye exam if on hydroxychloroquine.

Psychosocial Support

Visible skin disease can affect self‑esteem. Consider counseling, support groups, or patient‑advocacy organizations such as the Lichen Planus Association or Lupus Foundation of America.

Prevention

Because many triggers are modifiable, preventive steps can reduce flare frequency.

• Medication review – discuss alternatives with your clinician if you are on a known culprit drug.
• Sun avoidance – wear hats, UV‑protective clothing, and apply sunscreen daily.
• Smoking cessation – smoking worsens autoimmune skin disease.
• Hepatitis C screening and treatment – reduces risk of lichen planus in infected individuals.
• Allergy avoidance – patch test if contact dermatitis is suspected.

Complications

If left untreated or poorly controlled, interface dermatitis can lead to:

• Persistent scarring or pigmentary changes – especially after severe lichen planus or lupus lesions.
• Secondary skin infections – due to barrier disruption; bacterial (Staphylococcus) or fungal (Candida) superinfection.
• Oral complications – pain and difficulty eating with oral lichen planus; potential malignant transformation (<0.1 % risk) ⁴.
• Systemic involvement – in lupus, skin disease may herald renal, neurologic, or hematologic involvement.
• Quality‑of‑life impairment – chronic itch and visible lesions can cause anxiety, depression, and sleep disturbance.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. “Lichen planus.” https://www.mayoclinic.org/diseases-conditions/lichen-planus
2. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). “Cutaneous Lupus Erythematosus.” https://www.niams.nih.gov/health-topics/cutaneous-lupus-erythematosus
3. Wong SH, et al. “The prevalence of interface dermatitis in skin biopsies: a 5‑year review.” *Dermatopathology* 2022;30(4):215‑222.
4. Kumar S, et al. “Risk of malignant transformation in oral lichen planus: systematic review.” *J Oral Pathol Med* 2021;50(3):197‑206.